Who are Torisel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prezista, Clarinex, Allegra, Claritin, Versed, Cardizem.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/torisel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Torisel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Torisel (Temsirolimus) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: temsirolimus. Area: Oncology.

marketed temsirolimus Multidrug resistance protein 1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Torisel (Temsirolimus) — Pfizer. Temsirolimus is an inhibitor of mTOR, a protein that controls cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Torisel TARGET	Temsirolimus	Pfizer	marketed	temsirolimus	Multidrug resistance protein 1	2007-01-01
Prezista	DARUNAVIR	Janssen Prods	marketed	Protease Inhibitor [EPC]	Multidrug resistance protein 1	2006-01-01
Clarinex	desloratadine	Generic (originally Schering-Plough/MSD)	marketed	Histamine-1 Receptor Antagonist [EPC]	5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	2001-12-21
Allegra	fexofenadine	Generic (originally Hoechst Marion Roussel/Sanofi)	marketed	Second-generation antihistamine	Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor	1996-07-25
Claritin	loratadine	Generic (originally Schering-Plough)	marketed	Second-generation antihistamine	Sodium-dependent neutral amino acid transporter B(0)AT2, Cytochrome P450 2C19, Multidrug resistance protein 1	1993-04-12
Versed	midazolam	Generic (originally Roche)	marketed	Benzodiazepine (short-acting)	Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2	1985-12-20
Cardizem	diltiazem	Generic (originally Tanabe Seiyaku)	marketed	Calcium channel blocker (non-dihydropyridine, benzothiazepine)	Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1	1982-11-05

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-20 — Torisel · 8026276*PED · US
2028-01-18 — Versed · 8809322 · Formulation · US
2028-01-18 — Versed · 9687495 · Formulation · US
2028-01-18 — Versed · 9289432 · Formulation · US
2028-01-18 — Versed · 8217033 · Formulation · US
2032-05-10 — Torisel · 8791097 · US
2032-11-10 — Torisel · 8791097*PED · US
2038-06-20 — Versed · 10966990 · Formulation · US

Sponsor landscape (temsirolimus class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Torisel — Competitive Intelligence Brief. https://druglandscape.com/ci/torisel. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing